231 related articles for article (PubMed ID: 25980577)
1. Actionable mutations in plasma cell-free DNA in patients with advanced cancers referred for experimental targeted therapies.
Janku F; Angenendt P; Tsimberidou AM; Fu S; Naing A; Falchook GS; Hong DS; Holley VR; Cabrilo G; Wheler JJ; Piha-Paul SA; Zinner RG; Bedikian AY; Overman MJ; Kee BK; Kim KB; Kopetz ES; Luthra R; Diehl F; Meric-Bernstam F; Kurzrock R
Oncotarget; 2015 May; 6(14):12809-21. PubMed ID: 25980577
[TBL] [Abstract][Full Text] [Related]
2. Analysis of circulating DNA and protein biomarkers to predict the clinical activity of regorafenib and assess prognosis in patients with metastatic colorectal cancer: a retrospective, exploratory analysis of the CORRECT trial.
Tabernero J; Lenz HJ; Siena S; Sobrero A; Falcone A; Ychou M; Humblet Y; Bouché O; Mineur L; Barone C; Adenis A; Yoshino T; Goldberg RM; Sargent DJ; Wagner A; Laurent D; Teufel M; Jeffers M; Grothey A; Van Cutsem E
Lancet Oncol; 2015 Aug; 16(8):937-48. PubMed ID: 26184520
[TBL] [Abstract][Full Text] [Related]
3. Low incidence of KRAS, BRAF, and PIK3CA mutations in adenocarcinomas of the ampulla of Vater and their prognostic value.
Kwon MJ; Kim JW; Jung JP; Cho JW; Nam ES; Cho SJ; Kim JS; Park HR; Min SK; Seo J; Min KW; Kim DH; Jeon JY
Hum Pathol; 2016 Apr; 50():90-100. PubMed ID: 26997442
[TBL] [Abstract][Full Text] [Related]
4. Prospective blinded study of somatic mutation detection in cell-free DNA utilizing a targeted 54-gene next generation sequencing panel in metastatic solid tumor patients.
Kim ST; Lee WS; Lanman RB; Mortimer S; Zill OA; Kim KM; Jang KT; Kim SH; Park SH; Park JO; Park YS; Lim HY; Eltoukhy H; Kang WK; Lee WY; Kim HC; Park K; Lee J; Talasaz A
Oncotarget; 2015 Nov; 6(37):40360-9. PubMed ID: 26452027
[TBL] [Abstract][Full Text] [Related]
5. Liquid Biopsies Using Plasma Exosomal Nucleic Acids and Plasma Cell-Free DNA Compared with Clinical Outcomes of Patients with Advanced Cancers.
Möhrmann L; Huang HJ; Hong DS; Tsimberidou AM; Fu S; Piha-Paul SA; Subbiah V; Karp DD; Naing A; Krug A; Enderle D; Priewasser T; Noerholm M; Eitan E; Coticchia C; Stoll G; Jordan LM; Eng C; Kopetz ES; Skog J; Meric-Bernstam F; Janku F
Clin Cancer Res; 2018 Jan; 24(1):181-188. PubMed ID: 29051321
[No Abstract] [Full Text] [Related]
6. Noninvasive diagnosis of actionable mutations by deep sequencing of circulating free DNA in lung cancer from never-smokers: a proof-of-concept study from BioCAST/IFCT-1002.
Couraud S; Vaca-Paniagua F; Villar S; Oliver J; Schuster T; Blanché H; Girard N; Trédaniel J; Guilleminault L; Gervais R; Prim N; Vincent M; Margery J; Larivé S; Foucher P; Duvert B; Vallee M; Le Calvez-Kelm F; McKay J; Missy P; Morin F; Zalcman G; Olivier M; Souquet PJ;
Clin Cancer Res; 2014 Sep; 20(17):4613-24. PubMed ID: 25013125
[TBL] [Abstract][Full Text] [Related]
7. EGFR, KRAS, BRAF, and PIK3CA characterization in squamous cell anal cancer.
Martin V; Zanellato E; Franzetti-Pellanda A; Molinari F; Movilia A; Paganotti A; Deantonio L; De Dosso S; Assi A; Crippa S; Boldorini R; Mazzucchelli L; Saletti P; Frattini M
Histol Histopathol; 2014 Apr; 29(4):513-21. PubMed ID: 24122611
[TBL] [Abstract][Full Text] [Related]
8. Multiplex KRASG12/G13 mutation testing of unamplified cell-free DNA from the plasma of patients with advanced cancers using droplet digital polymerase chain reaction.
Janku F; Huang HJ; Fujii T; Shelton DN; Madwani K; Fu S; Tsimberidou AM; Piha-Paul SA; Wheler JJ; Zinner RG; Naing A; Hong DS; Karp DD; Cabrilo G; Kopetz ES; Subbiah V; Luthra R; Kee BK; Eng C; Morris VK; Karlin-Neumann GA; Meric-Bernstam F
Ann Oncol; 2017 Mar; 28(3):642-650. PubMed ID: 27993791
[TBL] [Abstract][Full Text] [Related]
9. Levels of cell-free DNA and plasma KRAS during treatment of advanced NSCLC.
Dowler Nygaard A; Spindler KL; Pallisgaard N; Andersen RF; Jakobsen A
Oncol Rep; 2014 Feb; 31(2):969-74. PubMed ID: 24316734
[TBL] [Abstract][Full Text] [Related]
10. Prevalence and heterogeneity of KRAS, BRAF, and PIK3CA mutations in primary colorectal adenocarcinomas and their corresponding metastases.
Baldus SE; Schaefer KL; Engers R; Hartleb D; Stoecklein NH; Gabbert HE
Clin Cancer Res; 2010 Feb; 16(3):790-9. PubMed ID: 20103678
[TBL] [Abstract][Full Text] [Related]
11. Cell-free DNA as biomarker and source for mutation detection in primary colorectal cancer.
Nikolic A; Vlajnic M; Ristanovic M; Petrovic J; Dimitrijevic I; Krivokapic Z; Radojkovic D
J BUON; 2017; 22(1):178-183. PubMed ID: 28365952
[TBL] [Abstract][Full Text] [Related]
12. Unique Genetic and Survival Characteristics of Invasive Mucinous Adenocarcinoma of the Lung.
Shim HS; Kenudson M; Zheng Z; Liebers M; Cha YJ; Hoang Ho Q; Onozato M; Phi Le L; Heist RS; Iafrate AJ
J Thorac Oncol; 2015 Aug; 10(8):1156-62. PubMed ID: 26200269
[TBL] [Abstract][Full Text] [Related]
13. Association of EGFR L858R Mutation in Circulating Free DNA With Survival in the EURTAC Trial.
Karachaliou N; Mayo-de las Casas C; Queralt C; de Aguirre I; Melloni B; Cardenal F; Garcia-Gomez R; Massuti B; Sánchez JM; Porta R; Ponce-Aix S; Moran T; Carcereny E; Felip E; Bover I; Insa A; Reguart N; Isla D; Vergnenegre A; de Marinis F; Gervais R; Corre R; Paz-Ares L; Morales-Espinosa D; Viteri S; Drozdowskyj A; Jordana-Ariza N; Ramirez-Serrano JL; Molina-Vila MA; Rosell R;
JAMA Oncol; 2015 May; 1(2):149-57. PubMed ID: 26181014
[TBL] [Abstract][Full Text] [Related]
14. High-resolution melting analysis as a sensitive prescreening diagnostic tool to detect KRAS , BRAF , PIK3CA , and AKT1 mutations in formalin-fixed, paraffin-embedded tissues.
Ney JT; Froehner S; Roesler A; Buettner R; Merkelbach-Bruse S
Arch Pathol Lab Med; 2012 Sep; 136(9):983-92. PubMed ID: 22938585
[TBL] [Abstract][Full Text] [Related]
15. BRAF mutation analysis in circulating free tumor DNA of melanoma patients treated with BRAF inhibitors.
Gonzalez-Cao M; Mayo-de-Las-Casas C; Molina-Vila MA; De Mattos-Arruda L; Muñoz-Couselo E; Manzano JL; Cortes J; Berros JP; Drozdowskyj A; Sanmamed M; Gonzalez A; Alvarez C; Viteri S; Karachaliou N; Martin Algarra S; Bertran-Alamillo J; Jordana-Ariza N; Rosell R
Melanoma Res; 2015 Dec; 25(6):486-95. PubMed ID: 26366702
[TBL] [Abstract][Full Text] [Related]
16. BRAF Mutation Testing in Cell-Free DNA from the Plasma of Patients with Advanced Cancers Using a Rapid, Automated Molecular Diagnostics System.
Janku F; Huang HJ; Claes B; Falchook GS; Fu S; Hong D; Ramzanali NM; Nitti G; Cabrilo G; Tsimberidou AM; Naing A; Piha-Paul SA; Wheler JJ; Karp DD; Holley VR; Zinner RG; Subbiah V; Luthra R; Kopetz S; Overman MJ; Kee BK; Patel S; Devogelaere B; Sablon E; Maertens G; Mills GB; Kurzrock R; Meric-Bernstam F
Mol Cancer Ther; 2016 Jun; 15(6):1397-404. PubMed ID: 27207774
[TBL] [Abstract][Full Text] [Related]
17. [Clinical implications of the concentration and EGFR/KRAS mutations of plasma cell free DNA of patients with lung cancer and esophageal cancer].
Zhang R; Li Y; Chen Y; Liu X; Wang Z; Sun H; Zheng Y; Ding Z; Lan L; Li M; Qin J; Chen X
Zhonghua Yi Xue Za Zhi; 2015 Dec; 95(47):3839-42. PubMed ID: 27337801
[TBL] [Abstract][Full Text] [Related]
18. Clinical Utility of Circulating Tumor DNA for Molecular Assessment and Precision Medicine in Pancreatic Cancer.
Takai E; Totoki Y; Nakamura H; Kato M; Shibata T; Yachida S
Adv Exp Med Biol; 2016; 924():13-17. PubMed ID: 27753011
[TBL] [Abstract][Full Text] [Related]
19. Correlation between PIK3CA mutations in cell-free DNA and everolimus efficacy in HR
Moynahan ME; Chen D; He W; Sung P; Samoila A; You D; Bhatt T; Patel P; Ringeisen F; Hortobagyi GN; Baselga J; Chandarlapaty S
Br J Cancer; 2017 Mar; 116(6):726-730. PubMed ID: 28183140
[TBL] [Abstract][Full Text] [Related]
20. A Targeted Q-PCR-Based Method for Point Mutation Testing by Analyzing Circulating DNA for Cancer Management Care.
Thierry AR
Methods Mol Biol; 2016; 1392():1-16. PubMed ID: 26843041
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
